Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088033 · ClinicalTrials.gov registry record · NA
Reduce Lap-hf Trial II
A NA study of Heart Failure, sponsored by Corvia Medical.
- Active
- Registry status
- NA
- Development phase
- 608
- Enrollment target
- 20
- Study locations
NCT03088033: Active NA study of Heart Failure, sponsored by Corvia Medical.
NCT03088033 is a NA study of Heart Failure that is active but no longer recruiting, run by Corvia Medical. The registered enrollment target is 608 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03088033, a NA study of Heart Failure, is active but no longer recruiting, sponsored by Corvia Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 608 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, Prospective, Randomized Controlled, Blinded Trial, with a Non-implant Control group; 1:1 randomization.
Primary Outcome
The primary endpoint is the composite of (a) incidence of and time-to-cardiovascular mortality or first non-fatal, ischemic stroke through 12 months; (b) total rate (first plus recurrent) per patient year of heart failure (HF) events, defined as hospital admissions, acute healthcare facility visits or urgent unscheduled outpatient visits for IV diuresis or intensification of oral diuretics for HF up to 24 months, analyzed when the last randomized subject completes 12 months follow-up, and time-t
Conditions Studied
Interventions
- DEVICE IASD System II implant
- OTHER intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Study Locations (20)
Florida
- Holy Cross Hospital - Fort Lauderdale
- Sarasota Memorial Hospital - Sarasota
- Tallahassee Research Institute, Inc. - Tallahassee
- Cleveland Clinic Florida - Weston
California
- Scripps Clinic - La Jolla
- Kaiser Permanente San Diego - La Jolla
- Kaiser Permanente San Francisco Medical Center - San Francisco
Illinois
- Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
- Evanston Northshore Healthcare - Evanston
Arizona
- Arizona Cardiovascular Research Center - Phoenix
- University of Arizona College of Medicine - Tucson
Louisiana
- Cardiovascular Institute of the South - Houma
- Ochsner Clinic Foundation - New Orleans
Massachusetts
- Tufts New England Medical Center - Boston
- Massachusetts General Hospital - Boston
Colorado
- South Denver Cardiology Associates - Littleton
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT03088033 still lists
NCT03088033 is an interventional study that assigns participants to a tested intervention. The registered 608 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which IASD System II implant is the first listed.
NCT03088033 names 20 study sites across 10 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03088033 about?
NCT03088033 is a clinical study titled "Reduce Lap-hf Trial II". Multicenter, Prospective, Randomized Controlled, Blinded Trial, with a Non-implant Control group; 1:1 randomization.
What is the current status of trial NCT03088033?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 608 participants. The study started on 2017-06-01. Estimated completion is 2026-09.
What conditions does trial NCT03088033 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03088033?
The interventions under investigation include: IASD System II implant (DEVICE), intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) (OTHER).
Who is sponsoring clinical trial NCT03088033?
This trial is sponsored by Corvia Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03088033 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03088033's enrollment target sits among peer trials
608 92nd of 397 higher than 306 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI